Selecta Biosciences – $74 Million IPO

New York – July 25, 2016 – Cooley advised the underwriters on Selecta Biosciences' $74.1 million initial public offering. The company's common stock now trades on The NASDAQ Global Select Market under the symbol "SELB."

UBS Investment Bank and Stifel acted as joint book-running managers for the offering. Canaccord Genuity and Needham & Company acted as co-managers for the offering.

Selecta is a clinical-stage biopharmaceutical company developing targeted immunotherapies using its proprietary synthetic vaccine particle, which are designed to modulate immune responses to treat and prevent disease.

The Cooley corporate and securities team advising the underwriters included Div Gupta, Marc Recht, Josh Kaufman, Brandon Fenn, Maggie Siegel, Mark Woodroffe and Colleen Hannigan.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Div Gupta Partner, New York
Marc Recht Partner, Boston
Josh Kaufman Partner, New York
Natasha Leskovsek Partner, Washington, DC
Wendy Goldstein Partner, New York
Ivor Elrifi Partner, New York
Matthew Pavao Partner, Boston
Francis Wheeler Partner, Colorado
Kenneth Krisko Partner, Reston
Christina Stock Special Counsel, Boston
Rena Kaminsky Special Counsel, Palo Alto
Phil Mitchell Partner, New York
Brandon W Fenn Associate, New York
Stephanie Gentile Partner, New York